Janus kinase inhibitor

AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO

Retrieved on: 
Wednesday, November 1, 2023
Janus, Online, Woman, Zoledronic acid, Biologic, Rheumatology, Population Health Management, Metabolic bone disease, Spondyloarthropathy, Systemic disease, Thrombosis, MRI, ANCA, Health care, Syndrome, Immunomodulation, Domain, Metabolism, Risk, Vasculitis, Inflammation, Osteoporosis, Adalimumab, Janus kinase inhibitor, Biomarker, Crystal, Rheumatoid arthritis, Alendronic acid, Social, Psoriatic arthritis, Use, Driver, Etanercept, PST, Metric, State, Paint, Pharmaceutical industry, Medical imaging, Health insurance, Book, Dentistry, Dietary supplement, Denosumab, Patient, Hand

THOUSAND OAKS, Calif., Nov. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its expanded rheumatology pipeline and portfolio, following the recent acquisition of Horizon Therapeutics. More than 20 abstracts will be presented during the American College of Rheumatology (ACR) Convergence 2023, taking place Nov. 10-15, in San Diego.

Key Points: 
  • Abstract #2161, Poster Session C: RA – Treatments Poster III, Tuesday, Nov. 14 from 9-11am PST
    Outcomes in Patients With Rheumatoid Arthritis Initiating Therapy With Etanercept, Adalimumab, or Janus Kinase Inhibitors
    Abstract #0441, Poster Session A: RA – Treatments Poster I, Sunday, Nov. 12 from 9-11am PST
    Treatment-Emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings
    Abstract #0236, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database
    Abstract #0237, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Abstract #0239, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Abstract #0242, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME)
    Abstract #1102, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1103, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1107, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1108, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Real-world Trends in the Use of Immunomodulation as Co-Therapy to Pegloticase: Claims-Based Findings Since 2016
    Abstract #1123, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1145, Poster Session B: Miscellaneous Rheumatic & Inflammatory Diseases Poster II, Monday, Nov. 13 from 9-11am PST
    Understanding Community Perspectives on Disease Management: A Social Media Analysis of Gout Care Strategies
    Abstract #1691, Oral Abstract Session: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA, Monday Nov. 13 from 5-5:10pm PST
    Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients With Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study
    Abstract #1690, Oral Abstract Session: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA, Monday Nov. 13 from 4:45-4:55pm PST
    Abstract #0966, Poster Session B: Epidemiology & Public Health Poster II, Monday Nov. 13 from 9-11am PST
    Abstract #1041, Poster Session B: Imaging of Rheumatic Diseases Poster I, Monday Nov. 13 from 9-11am PST
    Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients With Early Oligoarticular Psoriatic Arthritis: 16-Week Results From FOREMOST
    Abstract #1413, Poster Session B: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA, Monday Nov. 13 from 9-11am PST
    Abstract #1414, Poster Session B: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA, Monday Nov. 13 from 9-11am PST
    Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States
    Abstract #2528, Oral Abstract Session: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science, Tuesday, Nov. 14 from 4:15-4:25pm PST
    Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
    Abstract #2529, Oral Abstract Session: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science, Tuesday, Nov. 14 from 4:30-4:40pm PST
    Comparative Effectiveness of Denosumab versus Alendronate among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
    Abstract #2008, Poster Session C: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster, Tuesday, Nov. 14 from 9-11am PST
    Abstract #0683, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #0684, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #0685, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #0686, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #2379, Poster Session C: Vasculitis – ANCA-Associated Poster III: Biomarkers & Renal Outcomes, Tuesday, Nov. 14 from 9-11am PST
    Abstract #0171, Poster Session A: Health Services Research Poster I, Sunday, Nov. 12 from 9-11am PST
    Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren's Having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study
    Abstract #1636, Oral Abstract Session: Sjögren's Syndrome – Basic & Clinical Science, Monday, Nov. 13 from 2-3:30pm PST
    Abstract #1638, Oral Abstract Session: Sjögren's Syndrome – Basic & Clinical Science, Monday, Nov. 13 from 2-3:30pm PST
    Treatment Patterns and Drivers of Biologic Prescriptions in Patients with Primary Sjögren's Disease: Results from a Multinational, Real-World Survey
    Abstract #1369, Poster Session B: Sjögren's Syndrome – Basic & Clinical Science Poster I, Monday, Nov. 13 from 9-11am PST
    Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjögren's Syndrome
    Abstract #1379, Poster Session B: Sjögren's Syndrome – Basic & Clinical Science Poster I, Monday, Nov. 13 from 9-11am PST
    Disease Burden of Patients with Primary Sjögren's Disease: Results from a Multinational Real-World Survey
    Abstract #2179, Poster Session C: Sjögren's Syndrome – Basic & Clinical Science Poster II, Tuesday, Nov. 14 from 9-11am PST
    Osteoporosis Treatment Attributes and Levels for an Online Decision-Making Tool for Patients: Findings from Adaptive Choice-Based Conjoint Analysis
    Abstract #0688, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST

Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Monday, March 6, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Cream, Shift, Janus, American Academy, Chronic, Journal, Dermatology, Conference call, Patient, Interest, Hidradenitis suppurativa, American Academy of Dermatology, AAD, Janus kinase inhibitor, Inflammation, JAK1, Use, Adolescence, Atopic dermatitis, Randomness, Post hoc analysis, Autoimmunity, Maintenance, JAAD, Conference, Abstract, HS, Safety, Cryptocurrency, Pharmaceutical industry, Communications satellite, Disease, Vitiligo, Incyte

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2023 American Academy of Dermatology (AAD) Annual Meeting, held March 17-21, 2023, in New Orleans.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2023 American Academy of Dermatology (AAD) Annual Meeting, held March 17-21, 2023, in New Orleans.
  • “The research being featured at this year’s AAD Annual Meeting highlights the potential of Incyte therapies to meet the needs of patients living with vitiligo and other serious skin conditions,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte.
  • Saturday, March 18, 9:30 a.m. CT)
    Efficacy and Safety of Povorcitinib in Vitiligo: Results from a Phase 2, Placebo-Controlled, Dose Ranging Study (Session: S042 – Late-Breaking Research: Session 2.
  • They will also be published online via the Journal of the American Academy of Dermatology (JAAD) supplement in Fall 2023.

The 31st Annual Masters of Pediatric Dermatology Symposium Reveals New Faces Alongside An Updated Agenda This Coming February 2023

Retrieved on: 
Friday, January 20, 2023
Janus, Infection, Debate, Advisory board, Atopic dermatitis, Catalog, Student, Education, Pediatrics (journal), Face, DO, MS, The Croods: A New Age, Adelaide, Psoriasis, Health, Symposia, Faculty, Pediatrics, Partnership, Mercedes, Patient, Adolescence, American Academy, SGD, Dermatology, SOC, Doctor of Philosophy, Alopecia areata, Janus kinase inhibitor, Skin, Medicine, Pharmaceutical industry, Telehealth, MD

It has also partnered with the American Academy of Pediatrics' local chapters on various educational programs in support of advancing pediatric dermatology education.

Key Points: 
  • It has also partnered with the American Academy of Pediatrics' local chapters on various educational programs in support of advancing pediatric dermatology education.
  • This February, MOPD once again features a variety of pertinent sessions designed to provide the latest information to practicing professionals.
  • Led by world-renowned medical, aesthetic, and pediatric dermatology experts, LiVDerm empowers providers to educate, collaborate, and engage.
  • With a multipronged approach to mastering the myriad of subspecialties within the field, LiVDerm provides innovative and integrated education across the dermatology spectrum.

EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis  

Retrieved on: 
Friday, October 28, 2022
Janus, U.S. Securities and Exchange Commission, American College, Clinical trial, LinkedIn, Rheumatoid arthritis, Contrast, NASDAQ, Safety, Cancer, IIL, ACR20, Disease-modifying antirheumatic drug, Janus kinase inhibitor, GSK, III, Communication, Program, Annual report, Patient, Judgement, Industry, RA, Risk, Twitter, Health, American College of Rheumatology, Population, FSE, Pharmaceutical industry, MorphoSys

MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner, GSK plc (LSE/NYSE: GSK), provided an update on the ContRAst phase III program for otilimab as apotential treatment of moderate to severe rheumatoid arthritis (RA).

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner, GSK plc (LSE/NYSE: GSK), provided an update on the ContRAst phase III program for otilimab as apotential treatment of moderate to severe rheumatoid arthritis (RA).
  • The ContRAst phase IIl program enrolled a broad range of difficult-to-treat patients who had an inadequate response to or could not tolerate available treatments.
  • GSK is planning to submit full results from the ContRAst phase III program for publication in 2023.
  • As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients.

Brickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 12, 2022
CLK, Research, U.S. Securities and Exchange Commission, Stimulator of interferon genes, Pharmacokinetics, Next, Lists of diseases, Conference, Earnout, NDA, Health Canada, Private Securities Litigation Reform Act, Botanix Pharmaceuticals, LRRK2, Policy, COVID-19, Investor, TTK, AD, Clinical trial, Humanitarian use licenses, Acquisition, GLOBE, Atopic dermatitis, Inflammation, Company, Autoimmunity, Letter, Insurance, MDT, SAD, Trial of the century, MAD, DYRK1A, Time, Therapy, BioCompute Object, Economics, EDT, Nasdaq, Leadership, Patient, BBI, Janus kinase inhibitor, Intellectual property, Safety, Sale, Pharmaceutical industry, Vaccine, Video game, Brickell

BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • Research and development expenses were $6.0million for the first quarter of 2022, compared to $6.1million for the first quarter of 2021.
  • General and administrative expenses were $3.5million for the first quarter of 2022, compared to $3.0million for the first quarter of 2021.
  • Brickells net loss was $9.4million for the first quarter of 2022 compared to $9.0million for the first quarter of 2021.
  • Brickells management will host a conference call today at 4:30 p.m. EDT to discuss the financial results and recent corporate developments.

Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 15, 2022
Insurance, Trial of the century, Time, Research, Conference, Forgiveness, EDT, LRRK2, MAD, Atopic dermatitis, U.S. Securities and Exchange Commission, New Drug Application, Policy, Intellectual property, NDA, Cycloheximide, Autoimmunity, Acquisition, DYRK1A, Private Securities Litigation Reform Act, Income, Inflammation, COVID-19, Leadership, BBI, Next, Investor, TTK, Patient, Stimulator of interferon genes, Therapy, Nasdaq, SAD, Annual general meeting, American Academy, AD, Janus kinase inhibitor, Pharmacokinetics, Rheumatoid arthritis, GLOBE, Humanitarian use licenses, Safety, CLK, Company, Part, Pharmaceutical industry, Vaccine, Video game, Lithium, Brickell

BOULDER, Colo., March 15, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

Key Points: 
  • Revenue was $104.0thousand for the fourth quarter of 2021, compared to $27.0thousand for the fourth quarter of 2020.
  • Research and development expenses were $3.1million for the fourth quarter of 2021, compared to $4.6million for the fourth quarter of 2020.
  • General and administrative expenses were $3.3million for the fourth quarter of 2021, compared to $2.9million for the fourth quarter of 2020.
  • Brickells net loss was $6.1million for the fourth quarter of 2021 compared to $7.4million for the fourth quarter of 2020.

HSS Study Sheds Light on Real-World Treatment Patterns of Psoriatic Arthritis

Retrieved on: 
Tuesday, November 9, 2021
Janus, Safety, Arthritis, Uveitis, Depression, Hospital, Disease, Psoriatic arthritis, Metabolic syndrome, Insurance, Nonsteroidal anti-inflammatory drug, Hospital for Special Surgery, ACR, Diagnosis, HSS, TNF, Physician, Methotrexate, Skin, Patient, Janus kinase inhibitor, American College, MS, Pharmaceutical industry

"Regarding patient medication preferences, we found patients highly value preservation of their joint and function as well as safety," said lead study author Monica Schwartzman, MD, MS, a rheumatologist at HSS.

Key Points: 
  • "Regarding patient medication preferences, we found patients highly value preservation of their joint and function as well as safety," said lead study author Monica Schwartzman, MD, MS, a rheumatologist at HSS.
  • "We can use these findings to help us tailor our therapy to achieve the best outcomes for our patients."
  • PsA is a very heterogenous disease with five distinct patterns of arthritis, which can make it challenging to treat.
  • Preferences were ranked on a five-point Likert scale ranging from "not at all important" to "extremely important."

MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis

Retrieved on: 
Tuesday, July 27, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical trials, Tyrosine kinases, Branches of biology, Signal transduction, Pharmaceutical industry, Health sciences, Life sciences, Janus kinase inhibitor, Janus kinase, Jak, Boxed warning, Pharmaceutical industry in China, Medication

Janus Kinases (JAKs) are enzymes found in cells in the immune system that are critical for the cell signaling process.

Key Points: 
  • Janus Kinases (JAKs) are enzymes found in cells in the immune system that are critical for the cell signaling process.
  • That is only a fraction of the total market for anti-inflammatory drugs.
  • The FDA has issued Boxed Warnings for one of the marketed JAK inhibitor drugs used in the comparative study.
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms.

Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

Retrieved on: 
Wednesday, July 14, 2021
Tyrosine kinases, Branches of biology, Signal transduction, Organ systems, Tyrosine kinase 2, Galapagos NV, Psoriasis, Tyrosine kinase, Biology, Janus kinase inhibitor, Janus kinase 3 inhibitor

Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & Nasdaq: GLPG) reports positive topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients.

Key Points: 
  • Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & Nasdaq: GLPG) reports positive topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients.
  • Galapagos evaluated GLPG3667, a proprietary selective TYK2 compound, in a randomized, placebo-controlled, double-blind Phase 1b study in 31 patients with diagnosis of moderate to severe plaque psoriasis.
  • Main objectives were to evaluate the safety and tolerability of GLPG3667 as well as signs of clinical activity at Week 4.
  • Based on these results, we aim to initiate a global Phase 2b program in psoriasis next year as part of a program to develop our selective oral TYK2 inhibitor GLPG3667 broadly in inflammatory indications.

Insights on the Myeloproliferative Neoplasm Drugs Global Market to 2027 - Featuring Gamida Cell, Sierra Oncology & CTI BioPharma Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, June 28, 2021
Pharmaceutical, Health, Oncology, Tyrosine kinases, Myeloproliferative neoplasm, Janus kinase 2, Tyrosine kinase inhibitor, Cancer, Janus kinase inhibitor, Neoplasms

The "Myeloproliferative Neoplasm Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Myeloproliferative Neoplasm Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The various drug classes indicated for the treatment of myeloproliferative neoplasm are demethylation agents, tyrosine kinase inhibitor, multikinase inhibitors, JAK2 inhibitor, and others.
  • Key companies are focusing on strategies such as mergers and acquisitions, which is expected to drive the global myeloproliferative neoplasm drugs market growth.
  • Moreover, key players are focusing on product launches and product approvals to strengthen their presence in the global myeloproliferative neoplasm drugs market.